GLP-1 Receptor Agonists and Menstrual Cycle Changes: Clinical Considerations
Clinicians are seeing more patients ask about menstrual changes when treated with glucagon-like peptide-1 receptor agonists. Medications like semaglutide…
-
-
GLP-1 and Diet: What Foods Support Patient Nutritional Needs
Glucagon-like peptide-1 receptor agonists are now being used not just for diabetes management but also for treating obesity. These…
-
Common GLP-1 Medication Errors: What Patients and Healthcare Providers Need to Know
GLP-1 medications have completely changed how we treat type 2 diabetes and weight loss. Brands like Ozempic, Wegovy, and…
-
GLP-1 Medications Linked to Misuse in Eating Disorders
A new study in JAMA Psychiatry highlights a concerning trend with GLP-1 receptor agonists. Researchers found that 32 percent…
-
Oura and LillyDirect Partner to Enhance Support for GLP-1 Therapy Users
Oura and LillyDirect recently announced a strategic collaboration. This partnership supports patients utilizing GLP-1 therapies. Furthermore, LillyDirect customers receive…
-
Beyond Weight Loss How These Medications Benefit Heart Health
Cardiovascular disease and obesity represent two of the most consequential health challenges. Emerging evidence demonstrates that several receptor agonists…
-
Potential Benefits of GLP-1 Receptor Agonists in Type 1 Diabetes Management
Pharmaceutical companies originally developed glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter inhibitors to treat type 2 diabetes. Several of…
-
Do Weight-Loss Drugs Treat Sugar Addiction?
Clinicians are increasingly seeing patients who report an ongoing focus on sugar. These individuals often struggle to limit their…
-
Can GLP-1 Receptor Agonists Reduce Alcohol Consumption in Patients With Alcohol Use Disorder
Clinicians are increasingly recognizing glucagon-like peptide-1 receptor agonists as medications that have benefits beyond just controlling blood sugar. New…
-
GLP-1 Receptor Agonist Utilization Trends: What Real-World Data Reveals
Prescriptions for glucagon-like peptide-1 receptor agonists have grown significantly in the national health care system. Clinicians are seeing more…
